NCT03388632 2025-12-18Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersNational Institutes of Health Clinical Center (CC)Phase 1 Completed31 enrolled 20 charts